70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.
BACKGROUND Adjuvant chemotherapy (ACT) can be safely omitted in patients above 50 years of age with stage I-II hormone receptor positive (HR+) HER2-negative (HER2-) breast cancer and a low-risk 70-gene signature (MammaPrint®). However, the contribution of the 70-gene signature in high-risk subgroups by nodal involvemen...